Recombinant Human OLR1 Protein (C-6His)

Name: Recombinant Human OLR1 Protein (C-6His)
Brand: Beta LifeScience
SKU: BL-0521NP
Availability: InStock

BL-0521NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Oxidized Low-Density Lipoprotein Receptor 1 is produced by our Mammalian expression system and the target gene encoding Ser61-Gln273 is expressed with a 6His tag at the C-terminus.
Accession	P78380
Synonym	Oxidized Low-Density Lipoprotein Receptor 1; Ox-LDL Receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like Oxidized LDL Receptor 1; LOX-1; Lectin-Like oxLDL Receptor 1; hLOX-1; Lectin-Type Oxidized LDL Receptor 1; OLR1; CLEC8A; LOX1
Gene Background	Oxidized Low-Density Lipoprotein Receptor 1 (Ox-LDL Receptor 1) is a secreted, single-pass type II membrane protein which belongs to the C-type lectin superfamily. Ox-LDL Receptor 1 is expressed at high levels in endothelial cells and vascular-rich organs such as placenta, lung, liver, brain, aortic intima, bone marrow, spinal cord and substantia nigra. The expression of Ox-LDL Receptor 1 is induced by inflammatory cytokines such as TNF, IFNG and IL6 by pathological conditions, such as hyperlipidemia, hypertension and diabetes mellitus. Ox-LDL Receptor 1 mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (OxLDL) by vascular endothelial cells. Ox-LDL Receptor 1 association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. Ox-LDL Receptor 1 also binds to oxLDL, which acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. It also participates in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation.
Molecular Mass	25.39 KDa
Apmol Mass	30-35 KDa, reducing conditions
Formulation	Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2.
Endotoxin	Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity	Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity	Not tested
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage	For Research Use Only

Target Details

Target Function	Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
Subcellular Location	Cell membrane; Lipid-anchor. Cell membrane; Single-pass type II membrane protein. Membrane raft. Secreted. Note=A secreted form also exists. Localization to membrane rafts requires palmitoylation.
Database References	HGNC: 8133 OMIM: 602601 KEGG: hsa:4973 STRING: 9606.ENSP00000309124 UniGene: PMID: 28345638 LOX-1(+) CD15(+) polymorphonuclear myeloid-derived suppressor cells were elevated in hepatocellular carcinoma patients and suppressed T cell proliferation through ROS/Arg I pathway induced by ER stress. PMID: 29211299 High LOX-1 ligand activity as a risk factor for ischemic stroke. PMID: 28442661 The analysis also revealed that OLR1 is not required for the transcriptional regulation induced by oxidized PAPC but interestingly, OLR1 knockdown affected expression of CNN2, HMRR, ITGB6 and KIF20A, all genes governing cell proliferation and motility. PMID: 29103984 Data show that oxidized low density lipoprotein receptor 1 (LOX-1) is overexpressed in prostate cancer cells. PMID: 29107109 expression significantly higher in the arterial wall of epicardial coronary arteries compared to intramyocardial coronary arteries PMID: 29448251 let7g exerts a LOX1independent antiaging effect on endothelial cells. PMID: 29393358 high LOX-1 expression in pancreatic cancer tissues is indicative for the occurrence of lymph node metastases, high TNM stages and a poor prognosis. PMID: 29168159 lincRNAp21 is a major mediator of oxLDLinduced apoptosis and expression of LOX1 in human vascular endothelial cells, and acts via activation of PKCdelta. PMID: 28983628 this study shows that LOX-1 is involved in IL-1beta production and extracellular matrix breakdown in dental peri-implantitis PMID: 28898769 Results showed that the scFv with N-terminal fusing peptides proteins demonstrated increased LOX-1-binding activity without decrease in stability. These findings will help increase the application efficacy of LOX-1 targeting scFv in LOX-1-based therapy PMID: 29094051 The serum sLOX-1 level was higher in patients with large artery atherosclerotic stroke, and it was an independent predictor of functional outcome in patients with large artery atherosclerotic ischemic stroke. PMID: 27967338 LOX-1 has a role in atherogenesis and tumorigenesis as a potential link in these diseases [review] PMID: 29462603 the rs1050283 T allele of LOX-1 is strongly associated with an increased risk for atherosclerotic cerebral infarction in a Chinese population, which also affects levels of LOX-1 and sLOX-1 PMID: 27840386 data revealed that miR-let-7g exhibits anti-atherosclerotic activity, at least partially by targeting the LOX-1 signaling pathway. PMID: 28535009 High LOX1 expression is associated with colorectal cancer. PMID: 26895376 Increased LOX-1 expression in endothelial cells is potentially involved in the pathogenesis of sickle cell disease vasculopathy PMID: 27519944 LOX-1 signalling and the crucial role of cytokines PMID: 28860004 High OLR1 expression is associated with breast cancer. PMID: 28844714 Multiple classical molecular dynamics simulations have been applied to the human LOX-1 receptor to clarify the role of the Trp150Ala mutation in the loss of binding activity. Results indicate that the substitution of this crucial residue, located at the dimer interface, markedly disrupts the wild-type receptor dynamics PMID: 28657156 Carrying the C allele of the rs11053646 variant of the OLR1 gene was associated with an increased risk of CAD in heterozygous adult patients with FH, and this risk could be even greater in smokers as well as in younger patients. PMID: 28941610 Berberine could prevent the oxLDL and TNFalpha - induced LOX1 expression and oxidative stress, key events that lead to NOX, MAPK/Erk1/2 and NF-kappaB activation linked to endothelial dysfunction. PMID: 28511903 Individuals >/=30 years old with abdominal obesity presented lower Lox1 levels than patients >/=30 years old without abdominal obesity. PMID: 27525284 These studies suggest that activation of LOX-1 expression occurs through binding of the chlamydial glycan and provides one mechanism by which Chlamydia pneumoniae infection could play a role in the pathogenesis of atherosclerosis. PMID: 23821487 Elevated LOX1 is Associated with Acute Stroke. PMID: 27025681 Xanthine oxidase induces foam cell formation in large part through activation of LOX-1 - NLRP3 pathway in both vascular smooth muscle cells and THP-1 cells. PMID: 28084571 show that MiR-590-5p inhibits angiogenesis by targeting LOX-1 and suppressing redox-sensitive signals PMID: 26932825 OLR1 rs1050286 SNP may contribute to modify OLR1 susceptibility to acute myocardial infarction and coronary artery diseases. PMID: 26542080 Serum sLOX-1 level was significantly lower in the restless legs syndrome patient group compared to controls. PMID: 27546362 The mechanistic link between miR-590-5p and LOX-1:miR-590-5p downregulation led to LOX-1 upregulation in endothelial cells. PMID: 26906623 Serum LAB was associated with an increased carotid IMT in Japanese men, especially those with hypercholesterolemia PMID: 26892134 the current meta-analysis highlighted that variant allele of OLR1 rs11053646 G > C and PCSK9 rs505151 A > G may contribute to the susceptibility risk of ischemic stroke. PMID: 26666837 Silencing of LOX-1 gene expression abolished ox-LDL induced effects in cell viability, reactive oxygen species generation and gene expression. PMID: 26510581 both the 501>C single nucleotide polymorphisms in the LOX1 gene and the serum LOX1 level may be used to predict the development of left ventricular hypertrophy among essential hypertension patients. PMID: 24480971 for our Turkish sample group, LOX-1 30UTR188C/T and K167N polymorphisms may not be involved in susceptibility to GDM [gestational diabetes mellitus ] PMID: 26296941 Cholesterol depletion triggers the release of LOX-1 in exosomes as a full-length transmembrane isoform and as a truncated ectodomain soluble fragment. PMID: 26495844 Interaction between Lox-1, C-reactive protein and oxidized LDL play role in the pathogenesis of atherosclerosis. PMID: 26607724 OLR1 is a novel molecular link between the proliferative and inflammatory responses of vascular smooth muscle cells. PMID: 26305474 Ginkgo biloba extract inhibits oxLDL-induced matrix metalloproteinase activation by the modulation of the LOX1-regulated signaling pathway in human umbilical vein endothelial cells. PMID: 25080882 Data show that the interplay between the two TNF receptors (TNFR1 and TNFR2) was apparent in the expression pattern of lectin-type oxidized LDL receptor 1 (LOX-1) in response to TNF-alpha. PMID: 25416967 The serum LOX-1 levels were significantly higher in NAFLD patients than in healthy controls. PMID: 26185381 Low shear stress is a regulator of autophagy and LOX-1 plays an important role in shear stress induced autophagy. PMID: 25697875 results showed higher expression of HSP70 and LOX-1 in the placental tissues of pre-eclampsia patients which represent the possible contribution of these molecules in the disease pathogenesis. PMID: 24786389 Elevated plasma sLOX-1 level on admission independently predicts long-term all-cause mortality and MACE after STEMI. PMID: 25746549 biomarker for determining early endothelial damage in hypertension, especially in white coat hypertension PMID: 25007999 LOX-1 activation by oxLDL is an important event that enhances tumor angiogenesis PMID: 25170920 LOX-1 is the receptor that mediates oxidized LDL activity in vascular endothelial cells.Activation of LOX-1 causes endothelial dysfunction and vascular lipid deposition. PMID: 25463747 Our data indicate a new direction for LOX-1 regulation by the modulation of the PKCbeta/NAPDH oxidase/SIRT1/HSF1 mechanism PMID: 25982096 The present study showed that circulating soluble LOX-1 originates from coronary circulation and soluble LOX-1 and LOX-1 index are useful biomarkers for acute coronary syndrome. PMID: 24895597 Meta-analysis results showed that the +1073 C/T polymorphism in ORL1 decreased the risk of Alzheimer's disease. This allele was predicted to affect the binding site of many miRNAs explaining the relationship between the +1073 C/T variant and the disease. PMID: 25501227

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.